Compare FLUX & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLUX | TCRT |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 7.8M |
| IPO Year | 2019 | 2025 |
| Metric | FLUX | TCRT |
|---|---|---|
| Price | $0.25 | $1.61 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $1.87 | N/A |
| AVG Volume (30 Days) | 135.5K | ★ 1.5M |
| Earning Date | 11-03-2026 | 12-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.00 | ★ 24.66 |
| EPS | ★ N/A | N/A |
| Revenue | $9,317,000.00 | ★ $15,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $85.96 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 126.25 | N/A |
| 52 Week Low | $0.28 | $0.72 |
| 52 Week High | $1.83 | $4.50 |
| Indicator | FLUX | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 28.05 | 45.08 |
| Support Level | N/A | $1.61 |
| Resistance Level | $0.48 | $2.09 |
| Average True Range (ATR) | 0.05 | 0.17 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 0.43 | 20.34 |
Flux Power Holdings Inc. designs, develops, manufactures, and sells a portfolio of lithium-ion energy storage solutions for the electrification of a range of industrial and commercial sectors, which include material handling, airport ground support equipment (GSE), and stationary energy storage. It offers a high-power battery cell management system(BMS). The BMS serves as the brain of the energy storage solution, managing cell balancing, charging, discharging, monitoring, and communication between the pack and the forklift. The company's product portfolio includes Battery Technology and Energy Management solutions.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.